Xu Jing

Founding Partner

3 past transactions

Atantares

Seed Round in 2023
Atantares specializes in the application of semiconductor technology to enhance biomedicine, focusing on the development of precision medicines and advanced diagnostic devices. The company's microfluidics technology delivers ultra-high throughput and sensitivity, catering to the evolving demands of medical health, synthetic biology, and DNA storage. Atantares has created a coagulation device that facilitates the monitoring of specific drugs and blood products through coagulation assays, which assess platelet function, clotting times, and viscoelasticity using a proprietary biochip platform. Additionally, the company offers a chimeric antigen receptor designed to treat hematological tumors, cardiac diseases, neurological disorders, and cancer. This platform employs ultrasensitive immunoassays to provide critical cytokine profile data, aiding in the management of CAR T-cell therapy and mitigating cytokine release syndrome.

Degron Therapeutics

Series A in 2022
Degron Therapeutics is a drug discovery platform focused on developing a new class of targeted protein degradation therapeutics, specifically small molecule molecular glue degrader drugs. The company aims to become a leader in the discovery and development of these innovative medicines, which target disease mechanisms that are often inaccessible to traditional small molecule inhibitors. By leveraging its advanced molecular glue protein degradation platform technology, Degron Therapeutics identifies and validates disease targets while creating novel selective compounds. This approach addresses significant unmet medical needs across various therapeutic areas. The company boasts a team of experienced executives and scientific leaders dedicated to enhancing treatment efficiency through its drug development initiatives.

Metanovas Biotech

Seed Round in 2022
Metanovas Biotech specializes in the development of nutraceutical and cosmeceutical products utilizing advanced AI technology. The company offers a diverse product pipeline that includes pharmaceuticals, nutritional supplements, functional foods, and cosmetics, aimed at enhancing health and wellness for consumers. Metanovas employs an AI-enabled platform for drug and disease discovery, leveraging machine learning to identify novel disease targets, screen potential drugs, and optimize existing medications for new uses. This innovative approach allows for a more efficient generation of insights and the discovery of effective treatments, fundamentally transforming the intersection of science and artificial intelligence in health product development.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.